Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230023/S010

GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

W. L. Gore & Associates, Inc. · Decision date Jan 15, 2026

FDA DECISIONP230023/S010

What did the FDA approve?

FDA records P230023/S010 as a supplement to PMA P230023, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 15, 2026.

FDA approval order statement

approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230023.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jan 15, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P230023/S010
Regulatory pathway
PMA supplement
Product code
QZK
Decision code
APPR
Decision date
Jan 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.

Product code
QZK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230023/S010 received

    Application receipt date recorded by FDA.

  2. P230023/S009 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

  3. P230023/S010 · FDA decision

    Normal 180 Day Track No User Fee

  4. P230023/S011 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)

  5. P230023/S012 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230023

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3450 W. Kiltie Ln., Flagstaff, AZ, 86005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records